Allurion Technologies attracts buy ratings from financial analysts, with Roth MKM at $2.00 and Chardan Capital at $2.50.

Allurion Technologies (NYSE: ALUR), which focuses on obesity solutions, has attracted attention from financial analysts. Roth MKM initiated coverage with a buy rating and a $2.00 price target, while Chardan Capital lowered its target from $5.00 to $2.50 but maintained a buy rating. The company reported earnings of $0.01 per share and revenue of $11.77 million. Institutional investors hold about 21.39% of its stock.

September 07, 2024
3 Articles

Further Reading